April 18 (Reuters) - Cerevel Therapeutics said on Thursday its Parkinson's disease drug met the main goal of a late-stage trial. (Reporting by Sriparna Roy in Bengaluru; Editing by Savio D'Souza)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
42.17 USD | -0.05% | -0.92% | -0.64% |
05-08 | Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-18 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.64% | 7.69B | |
+5.10% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.30% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-9.59% | 16.85B | |
+4.56% | 13.76B | |
+34.90% | 12.46B |
- Stock Market
- Equities
- CERE Stock
- News Cerevel Therapeutics Holdings, Inc.
- Cerevel Therapeutics' Parkinson's disease drug meets main goal in late-stage study